Phone (201) 584-7093 or (800) 370-2222 FAX (978) 371-2266
Press Release from Research Diagnsotisc Inc
:
Updated June 18, 1996
sCD27-A Novel Tumor Marker
CD27 is a transmembrane disullfide-linked glycoprotein found exclusively on human T and B lymphocytes. It belongs to the TNFr receptor superfamily for membrane bound and soluble cytokines, whose members are involved in cell differentiation and survival. A soluble form of CD27 (sCD27) is released into the supernatant of activated T-cells and found in serum and urine of healthy individuals. Levels of sCD27 have been found to increase in patients suffering from a variety of immunopathological diseases which suggests that measurements of sCD27 can serve as a marker for T-cell activation.
A recent study published in March 1996 issue of Blood shows that measurement of sCD27 is a new, acccurate and sensitive parameter for the diagnosis of meningeal metastasis of lymphoid malignancies.
Children with ALL and NHL have a particular high risk of developing
meningeal localizations. Although all these children, even without clinical
evidence, are routinely examined for meningeal localization in CSF, they are
nevertheless undergoing central nervous system staging as precaution. To
prevent this often unnecessary treatment the sCD27 marker will be a very
important diagnostic tool.
Until now, diagnosis of meningeal localization depended upon cytological
examination of cerebrospinal fluid (CSF) and could result in false negative
rates of 40% during early meningeal involvement.Tthe value of additional
immunocytology is limited because of its low sensitivity, while other tumor
markers such as B2 microglobulin and TNF-alpha show a poor specificity.
The study comprised five patient group:
|
Group |
Patients |
Samples |
results sCD27 assay |
|
I |
50 controls |
50 |
all negative |
|
II |
70 children (55 ALL, 15 NHL) |
104 |
specificity 96% sensitivity 83% accuracy 98% |
|
III |
45 patients suspected of meningeal localization of ALL or NHL |
144 |
specificity 82% sensitivity 100% accuracy 89% |
|
IV |
4 patients with primary cerebral lymphoma (PCL) |
8 |
7 positive whereas cytology was negatove |
|
V |
32 patients with either myeloid leukemia or solid tumors suspected of meningeal metastasis |
40 |
1 sample positive |
The reuslts of the sCD27 assay were compared to cytology, combined with clinical follow-up and B2-microglobulin levels. (HIV seropositive patients were excluded).
Furthermore, it was shown that CSF-sCD27 discriminates excellently between
meningeal and/or cerebral involvement by either a lymphoid malignancy or a soid
tumor. It is also found to be a reliable marker for remission and relapse.
sCD27 is a diagnostic test in this study superior to B2 microglobulin levels.
Literature:
1. Kersten MJ, EVers LM, Portegies P, Dellemijn PLI, von dem Borne AEGKR, van Lier RAW, van OERS MHJ,
ELEVATION OF CEREBROSPINAL FLUID SOLUBLE CD27 LEVELS IN PATIENTS WITH MENINGEAL LOCALIZATION OF LYMPHOID MALIGNANCIES, Blood Vol 87, no 5:pp 1985-1989, 1996.
The Pelikine-compact kit (manufactured by C:LB Reagents-a division of the Netherlands Red Cross) for measuring sCD27 is available through Research Diagnostics Inc for in vitro research use only-not for use in diagnostics or diagnostic procedures.
Please request the sCD27 kit insert, catalog#RDI-M1960clb, new cat#: 55R-M1960clb
For additional antibodies against CD27 for use in flow cytometry, ELISA and hiostochemistry, see our antibody section CD27 antibodies.
RDI Division of Fitzgerald Industries Intl
phone (201) 584-7093
fax (978) 371-2266